Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Nov. 30, 2025
Nov. 30, 2024
Revenue $ 31,566,321 $ 31,986,106
Costs and Expenses:    
Cost of sales 7,376,648 7,947,752
Selling, general and administrative expenses 18,220,708 18,524,012
Impairment of public inventory 4,358,834 0
Research, development and related engineering 376,263 1,242,536
Depreciation and amortization 751,474 483,522
Total costs and expenses 31,083,927 28,505,822
Operating Income 482,394 3,480,284
Other Income (Expense):    
(Losses) gains on marketable securities (806,267) 1,076,051
Gain on interest rate swap 0 105,887
Other income 52,976 6,583
Interest expense (2,066,256) (1,864,684)
Total other (expense) income (2,819,547) (676,163)
(Loss) income before income tax expense (2,337,153) 2,804,121
Income tax expense (92,232) (2,402,026)
Net (loss) income $ (2,429,385) $ 402,095
Net (loss) income per common share - basic $ (0.30) $ 0.05
Weighted average common shares outstanding - basic 8,068,777 8,130,676
Net (loss) income per common share - diluted $ (0.30) $ 0.05
Weighted average common shares outstanding - diluted 8,068,777 8,212,510
Tianhe Stem Cell Biotechnologies Inc [Member]    
Costs and Expenses:    
Impairment of investment $ 0 $ 308,000
Processing and Storage Fees [Member]    
Revenue 31,382,704 31,551,550
Public Banking Revenue [Member]    
Revenue 129,513 366,672
Product [Member]    
Revenue $ 54,104 $ 67,884